Novo research chief says 'jury still out' on CagriSema at ADA
Comments came as the amylin-GLP-1 combination drew comparisons with Eli Lilly's triple agonist retatrutide at the diabetes meeting.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 10 03:00 ETSource: fiercebiotech.com
The wire
- 01Novo Nordisk's Lange told the American Diabetes Association meeting the 'jury is still out' on CagriSema as it is measured against retatrutide.
- 02CagriSema is Novo's lead next-generation obesity candidate, and executive framing of its competitive position shapes payer and prescriber expectations.
- 03No head-to-head trial of CagriSema and retatrutide has been reported, so cross-trial comparisons remain the only available basis.
From the source
Read at fiercebiotech.comADA: Novo’s Lange says ‘jury still out’ on CagriSema amid tough retatrutide comparisons